Jilin Province Huinan Changlong Bio-pharmacy Company Limited (Jilin Changlong) filed its Monthly Return for Equity Issuer with Hong Kong Exchanges and Clearing Limited for the period ended 31 May 2026, confirming stable share capital and compliance with listing requirements.

The company reported no changes in its authorised or registered share capital during May. Authorised capital remains at 560.25 million ordinary shares with a par value of RMB 0.1 each, equivalent to RMB 56.03 million. This is split between 172.50 million H shares (RMB 17.25 million) listed on GEM and 387.75 million unlisted domestic shares (RMB 38.78 million).

Issued share numbers were also unchanged. As of 31 May 2026, Jilin Changlong had 172.50 million H shares and 387.75 million domestic shares issued, totalling 560.25 million shares. The company held no treasury shares.

Jilin Changlong confirmed that the public float for its H shares meets the initial prescribed minimum threshold of 25% as required under the GEM Listing Rules.

During the month, the issuer reported no new share options, warrants, convertible securities, other share-issue arrangements or movements in treasury shares. No Hong Kong Depositary Receipts are in issue.

The filing was signed by Company Secretary Mok Sai Cheong Mark on 2 June 2026.